Würzburg, Germany

Andreas Rosenwald


 

Average Co-Inventor Count = 23.6

ph-index = 1


Location History:

  • Wurzburg, DE (2020 - 2023)
  • Würzburg, DE (2021 - 2023)

Company Filing History:

goldMedal5 out of 3,435 
 
National Institutes of Health, a Component of the US Dept. of Health & Human Services
 patents
silverMedal5 out of 21 
 
Hospital Clinic De Barcelona
 patents
bronzeMedal4 out of 61 
 
British Columbia Cancer Agency Branch
 patents
44 out of 47 
 
UniversitÄt De Barcelona
 patents
54 out of 6 
 
Julius-maximilians-university of Wurzburg
 patents
64 out of 11 
 
Oslo University Hospital Hf
 patents
73 out of 972 
 
University of Arizona
 patents
83 out of 730 
 
University of Nebraska
 patents
93 out of 504 
 
Oregon Health & Science University
 patents
102 out of 1,742 
 
Mayo Foundation for Medical Education and Research
 patents
112 out of 1,036 
 
The Cleveland Clinic Foundation
 patents
122 out of 88 
 
University of London
 patents
132 out of 970 
 
University of Rochester
 patents
141 out of 3 
 
British Columbia Cancer Agency
 patents
151 out of 1 
 
Universitat De Barceloa
 patent
161 out of 1 
 
Institut D'investigacions Biomédiques Pi I Sunyer (Idibaps)
 patent
171 out of 1 
 
Robert Bosch Gesellschaft Feuer Medizinische Forshung Mbh
 patent
181 out of 639 
 
City of Hope
 patents
191 out of 2 
 
Fundacio Clinic
 patents
where one patent can have more than one assignee

Years Active: 2020-2023

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Andreas Rosenwald

Introduction

Andreas Rosenwald is a notable inventor based in Würzburg, Germany. He has made significant contributions to the field of lymphoma research, holding three patents that focus on methods for diagnosing and treating various types of lymphoma. His work has the potential to greatly impact patient care and treatment options.

Latest Patents

Rosenwald's latest patents include a method for determining lymphoma type and providing treatment. This invention offers a way to distinguish between different lymphoma types based on gene expression measurements. Specifically, it can differentiate between primary mediastinal B cell lymphoma (PMBCL) and diffuse large B cell lymphoma (DLBCL) using gene expression signatures. Furthermore, it can identify subtypes of DLBCL, which can be crucial for tailoring treatment approaches.

Another significant patent is directed towards subtyping lymphoma types through expression profiling. This method allows for the selection of treatment options for various lymphoma subjects, including activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) and germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL). By analyzing digital gene expression data obtained from biopsy samples, this invention enhances the precision of lymphoma treatment.

Career Highlights

Throughout his career, Rosenwald has worked with prestigious institutions, including the National Institutes of Health, a component of the US Department of Health & Human Services, and the Hospital Clinic de Barcelona. His experience in these organizations has contributed to his expertise in lymphoma research and treatment methodologies.

Collaborations

Rosenwald has collaborated with esteemed colleagues, including Louis M. Staudt and George W. Wright. These partnerships have likely enriched his research and led to advancements in the understanding of lymphoma.

Conclusion

Andreas Rosenwald's innovative work in lymphoma research exemplifies the impact of scientific inquiry on medical treatment. His patents not only advance the field but also hold promise for improving patient outcomes in lymphoma care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…